- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The PSA Debate Continues
The Lancet study, conducted in Europe, found a survival benefit with early diagnosis, but does not agree that the benefit outweighs some of the associated risks of the test.
The value of the PSA test to screen men for prostate cancer has long been debated, and a new study of 162,000 men may not resolve the issue.
The Lancet
The European study, reported Aug. 6 in , finds that widespread use of prostate-specific antigen (PSA) blood tests does reduce deaths from the disease by about one-fifth.
However, due to lingering doubts about whether the benefits of PSA screening outweigh the risks, the study's authors still recommend against routine use of the test at this time.
"PSA screening delivers a substantial reduction in prostate cancer deaths, similar or greater than that reported in screening for breast cancer," study lead author Fritz Schroder, of the Erasmus University Medical Center in the Netherlands, said in a journal news release.
"However, overdiagnosis occurs in roughly 40 percent of cases detected by screening resulting in a high risk of overtreatment and common side effects such as incontinence and impotence," he added.
Read the report here: http://bit.ly/1ogohQK
Source: US News
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
